Nearly 80% of patients with metastatic uveal melanoma experienced skin toxicities with tebentafusp, a targeted immunotherapy, according to a study that also suggests that the presence of skin reactions is associated with improved survival.
Clinical Trials
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma
The phase 3 IOB-013/KN-D18 trial (NCT05155254) evaluating IO102-IO103 in combination with pembrolizumab (Keytruda) for the first-line treatment of patients with advanced melanoma will continue without modifications following a recommendation from an independent data monitoring committee (IDMC).
Early Phase I data shows promise for mRNA cancer immunotherapy in advanced solid cancers
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
Melanoma Treatment Advances: Fianlimab and Cemiplimab Show Promise
A longer-term follow-up of a study evaluating fianlimab, an anti-LAG-3 agent, and cemiplimab (Libtayo), an anti-PD-1 agent, is being presented as a poster at this year’s European Society for Medical Oncology (ESMO) Congress.